Introduction
Menopause is the permanent cessation of menstruation resulting from the loss of ovarian follicular activity [1] . It is estimated that perhaps 50 million women worldwide will reach menopause annually [2] . Menopause has been shown to contribute to development of central obesity, insulin resistance and impaired glucose and lipid metabolism which all increase the risk of cardiovascular disease in women [3] . Postmenopausal health consequences are believed to be related to low oestrogen levels, which characterize the hormonal milieu of postmenopausal women. However, the fact that postmenopausal complications are not universal in the female population illustrates the multifactorial nature of these disorders, where environmental and genetic factors contribute to the phenotypic expression of a given complication [2] .
Apolipoprotein E gene (APOE) codes a glycoprotein that plays a central role in lipid metabolism. ApoE binds with high affinity to the low density lipoprotein (LDL) receptor and facilitates endocytosis of the associated lipoprotein particle [4] . The human APOE gene is located on chromosome 19q13.2 and consists of 3.7 kb DNA including 4 exons and 3 introns encoding for a polypeptide of 299 aminoacids [5] . A single nucleotide polymorphism (SNP) in the APOE gene (rs429358, rs7412) is characterized by a single base substitution of the two nucleotides, T→C and C→T, which cause amino acid substitution of cysteine (Cys) and arginine (Arg). The E3 is the most common of the three protein isoforms, and is distinguished by Cys at position 112 and Arg at position 158 in the receptor-binding region of the apoE. The E2 isoform has Cys in both positions, while the E4 isoform has Arg in both positions [6] .
The APOE*4 allele is associated with increased levels of LDL cholesterol (LDL-C) and apolipoprotein B (apoB), and decreased levels of apolipoprotein A1 (apoA1) and high density lipoprotein cholesterol (HDL-C) [7] . This increases susceptibility to heart disease and atherosclerosis [8] . Almeida et al. [9] have suggested that the influence of hormonal replacement therapy (HRT) on total cholesterol (TC) and LDL-C is modulated by APOE genotypes, as total-C and LDL-C concentrations in postmenopausal APOE*4 carriers who used HRT were similar to those in the postmenopausal homozygote APOE*3 and APOE*2 carriers who did not use HRT. Although Oh et al. [10] and Lee et al. [11] report positive associations between APOE genotypes and obesity phenotypes, no such associations were observed by Nicklas et al. [12] and Guerra et al. [13] . Kee et al. [14] showed that subjects carrying at least one APOE*4 allele had a significantly reduced response to weight loss through decreasing total cholesterol and apolipoprotein serum levels. Lee et al. [11] observed that APOE*3/3 genotype led to a higher prevalence of metabolic syndrome and obesity than the other APOE genotypes in postmenopausal Korean women. The APOE*4 allele has been found to be a major genetic risk factor for Alzheimer's disease [15] and it has also been associated with osteoporosis in postmenopausal females [16] . Niculescu et al. [17] propose that the combination of APOE*2 and CETP B2 (cholesteryl ester transfer protein) alleles may play a protective role in successful ageing and longevity.
There have been no previous reports on the APOE polymorphism related to obesity and metabolic parameters in Slovak women with respect to their menopausal status. Therefore, we investigated how various isoforms of the APOE polymorphism influence these variables in women with respect to their menopausal status.
Experimental Procedures

Study sample
This study was based on data collected during crosssectional surveys in Slovakia between 2004 and 2011, in order to analyze the effect of genetic variants of some candidate genes on biomarkers of health in Slovak women. The complete sample was composed of 447 women ranging in age between 39 and 90 years, with a mean age of 56.37±12.72. The participants provided all the required anthropometrical, genetic and biochemical data. From this sample, 427 participants were also typed for HDL-C, LDL-C, apoA1 and apoB.
Participants were recruited from different localities in the western, southern and middle parts of Slovakia via an invitation letter regarding the study which was circulated and distributed prior to data collection with the help of local medical doctors. Volunteers were then interviewed during their routine health check and, after giving written Informed Consent for this study, they were investigated in regard to their medical, anthropometrical and lifestyle aspects at local Health Centres. However, only selected variables were considered for the purpose of this paper. Women who had undergone acute disorders such as cancer, myocardial infarction, or stroke were not included in the survey. All included women, and particularly those above 60 years, were assessed as free from serious physical handicaps or Alzheimer's and Parkinson´s diseases at the time of their recruitment. This entire sample was divided into three subgroups; premenopausal and perimenopausal women (n=175, 39-56 years, 45.57±3.93); early postmenopausal women, 1-10 years after the final menstrual period (FMP) (n=129, 41-70 years, 53.40±4.73) and late postmenopausal women, 11 and more years after FMP (n=143, 53-90 years, 72.26±7.96). The women in this study were considered to be perimenopausal if they reported that their menstrual cycle length had become more irregular in the preceding 12 months or that they had stopped menstruating for between 3 and 12 months, and women were considered to be postmenopausal if they reported 12 consecutive months of amenorrhoea for which there was no other obvious pathological or physiological cause, in accordance with the definition of WHO [1] .
Anthropometric and blood pressure analysis
Anthropometrical measurements of body height, body weight, waist (WC) and hip (HC) circumferences were carried out according to the technique of Knussmann [18] . Body height was measured at the head level, with 0.5 cm accuracy, with a Sieber and Hegner anthropometer with the participant standing barefoot with feet together.
Body weight was measured on a personal balance scale with the participant in underwear only, with an accuracy of 0.1 kg. The WC and HC were measured to the nearest 0.5 cm using a non-stretchable tape measure, with the participant standing. The WC was measured at the level of the umbilicus and the HC was measured at the maximum posterior protrusion of the buttocks. The body mass index (BMI) was calculated as body weight divided by height squared. The waist to hip ratio (WHR) was calculated by waist circumference divided by hip circumference. These anthropometric parameters were all measured by professional anthropologists, with the same instruments used for all participants. Inter-and intra-observer variability in WC and HC measurements was established at less than 0.5 cm, prior to these investigations. Blood pressure (BP) was measured in the morning during medical examination, in the sitting position using a mercury sphygmomanometer.
Biochemical analysis
Venous blood was collected following overnight fasting. The plasma was separated and biochemical analysis of TC, triglycerides (TG), HDL-C, apoA1 and apoB, were carried out by routine laboratory methods in the Department of Clinical Laboratories of the Bratislava Alpha Medical. The LDL-C levels were calculated using the Friedewald formula [19] . The atherogenic indices were calculated as follows: apoB-to-apoA1 ratio, TC-to-HDL-C ratio, LDL-C-to-HDL-C ratio, log (TG-to-HDL-C ratio) and nonHDL-C as TC minus HDL-C.
Genetic analysis
Genomic DNA was isolated from peripheral blood leukocytes by the standard phenol extraction technique or using the SiMax™ Genomic DNA Extraction kit (E. coli). PCR-RFLP detected the presence of the APOE*2, APOE*3, APOE*4 alleles, and PCR amplification was accomplished using two sets of primers: P1 5´-GGC CCA GGC CCG GCT GGG CGC GGA-3´; P2 5´-CGG ATG GCG CTG AGG CCG CGC TCG-3´. The DNA fragments digested with HhaI restriction enzyme (New England BioLabs), as described by Hixson and Vernier [20] , were separated by electrophoresis on 4% agarose gel (SFR -Super Fine Resolution, Amresco). Six genotypes, comprising the three homozygotes E*2/2, E*3/3, E*4/4 and three heterozygotes E*3/3, E*4/2, E*4/3 were divided into three isoform groups. The E2 group included E*2/2 and E*3/2 genotypes, the E3 group included the E*3/3 genotype and the E4 group had E*3/4 and E*4/4 genotypes. The E*2/4 genotype (n=7) was excluded from analysis because of the putative opposite effects of these two alleles on cardiovascular risk factors.
Statistical analysis
The Chi-square test was performed to confirm whether the observed genotype counts fell within the HardyWeinberg equilibrium. The normality assumption hypothesis was tested by the one-sample KolmogorovSmirnov test. Statistical comparisons of anthropometric variables were tested by univariate analysis of covariance (ANCOVA), with age and years after FMP as the covariates. Since the biochemical parameters are likely to be modulated by a number of factors such as age, years after FMP, BMI and WHR, statistical comparisons were also analyzed by the ANCOVA model with control for these confounders, and the results were expressed as mean ±SD. Differences of P<0.05 were considered to be statistically significant. ANCOVA was also used to analyze the dependence of blood pressure, lipid and lipoprotein levels on APOE alleles and menopausal group as risk factors following control for age, years after FMP, BMI and WHR. The parameter estimates were calculated using a regression analysis. Bonferroni correction was used to test post hoc comparisons. The effect of menopausal group and APOE group on obesity indices was also tested by ANCOVA, the regression analysis and the Bonferroni correction. The effect of APOE polymorphism on selected cardiovascular risk factors was tested by stepwise logistic regression (Forward Wald method), and the risk ratios were also evaluated. All statistical computations were performed with the SPSS 17.0 software programme (SPSS Inc., Chicago, IL).
Results
The genotype distribution and allele frequencies in the entire sample fell within the Hardy-Weinberg equilibrium (χ2=0.024, P>0.05). The APOE allele frequencies were as follows: E*2=5.36%, E*3=84.46% and E*4=10.18%. The complete sample in Table 1 shows statistically significant differences in the mean values of particular variables between the three APOE genotype groups, even after adding age and years after FMP, BMI and WHR as confounding factors; sBP (F=3.97, P=0.020), TC (F=6.43, P=0.002), LDL-C (F=11.03, P<0.001), apoA1 (F=3.46, P=0.032), apoB (F=9.23, P<0.001), apoB-to-apoA1 ratio (F=14.45, P<0.001), TC-to-HDL-C ratio (F=4.38, P=0.013), nonHDL-C (F=9.07, P<0.001), LDL-C-to-HDL-C ratio (F=10.31, P<0.001).
Analysis of covariance with menopausal group and APOE group as risk factors revealed the APOE effect on systolic blood pressure and lipid levels, as depicted in Table 2 . However, the impact of menopausal group was not confirmed at P>0.05. A significant impact of particular genotypes on the investigated parameters was evident in the following variables; sBP (F=4.25, P=0.015), LDL-C (F=11.05, P<0.001), apoA1 (F=3.26, P=0.039), apoB (F=9.43, P<0.001), apoB-to-apoA1 (F=14.26, P<0.001), TC-to-HDL-C (F=3.70, P=0.025), non-HDL-C (F=9.60, P<0.001) and LDL-C-to-HDL-C (F=10.77, P<0.001), even after adding the age, years after FMP, WHR and BMI as confounding factors. The regression analysis shown in Table 3 for the whole sample confirmed the effect of APOE genotype on the above parameters, except for the apoA1 levels (for which the P-value was not significant, P=0.471). Table 4 shows the results of the Bonferroni corrected post hoc comparisons. The difference in the sBP between the E4 and E3 genotype groups remained significant (P=0.006), with lower estimated marginal mean values in E4 carriers compared to the E3 group (124.1 mm/Hg vs. 129.7 mm/Hg, mean difference =-5.613, 95% CI -10.462, -0.764). Significant differences between E2 and E4 and E2 and E3 were not confirmed (P=0.484). LDL-C levels, apoB levels, non HDL-C and LDL-to-HDL-C values significantly differed between E2 and both E3 and E4 at P<0.05. Here, lower mean levels were registered in E2 carriers than in E3 and E4 subgroups. The significant difference between E4 and E3 was not confirmed (P>0.05). ApoB-to-apoA1 values significantly differed between all three APOE groups (E2 vs. E3 and E4, E4 vs. E3), with a lower mean value registered in E2 carriers than in E3 and E4 subgroups, and with a higher mean value recorded in E4 carriers than in the E3 subgroup (P<0.05). TC-to-HDL-C values significantly differed only between E2 and E4 groups (P=0.024). The Bonferroni test did not confirm any difference in apoA1 levels between the APOE genotype groups (P>0.05). Table 3 . Regression analysis of selected confounder effects on blood pressure and lipid levels in Slovak women.
and WHR obesity indices was confirmed. However, ANCOVA revealed a statistically significant interaction between the menopausal group and the APOE genotype groups and their common effect on WHR, even after control for age and years after FMP (Table 2 ). This effect was also confirmed by the regression analysis documented in Table 5 (B=0.103, SE=0.037, 95% CI 0.031-0.175, P=0.005). Table) .
The effect of APOE genotypes on the selected cardiovascular risk factors of obesity, central obesity, hypertension and hypercholesterolaemia in Slovak women is recorded in Table 7 . Stepwise logistic regression analysis confirmed the effect of the APOE genotype on hypercholesterolaemia expressed as LDL-C>3.00, even after adding age, years after FMP, BMI and WHR as confounding factors. An almost threefold higher risk of hypercholesterolaemia development was recorded in Slovak women with the E*3/3, E*3/4 or E*4/4 genotypes than in those with the E2 allele (Exp(B)=2.914; 95% CI 1.245-6.821).
Discussion
In this cross-sectional study, the mean levels of LDL-C detected were higher in the E4 and E3 carriers than in the E2 carriers even after control for age and years after FMP, BMI and WHR. The same results were obtained for apoB, apoB-to-apoA1 ratio, nonHDL and LDLto-HDL ratio. However, we did not confirm the effect of menopausal status on these parameters, and also interaction between the menopausal group and the APOE group had no impact on lipids and lipoprotein levels. In this respect, our results do not agree with Schaefer et al. [21] who showed that the association between APOE genotype and LDL-C level is stronger in postmenopausal women than in premenopausal women, and also stronger than in men. These authors reported that in general, the APOE*2 allele can lead to lower plasma LDL-C in Caucasian women by an average 0.21 mmol/l in premenopausal women or 0.52 mmol/l in postmenopausal women. The effect of menopause on LDL-C levels also significantly varied in Japanese women depending on their APOE genotype Table 5 . The effect of menopausal group and APOE genotype as risk factors on waist-to-hip ratio in Slovak women.
Values represent mean ± SD. [22] . Among subjects in the postmenopausal group, LDL-C level was approximately 1.2 mmol/l higher in the APOE*4 carriers than in the APOE*2 carriers; the difference between these two genotypes was smaller in premenopausal women. Eichner et al. [23] , revealed no such difference between pre-and postmenopausal Caucasian women, while Kamboh et al. [24] observed in their study of Hispanic women that there was an APOE polymorphism effect on TC and LDL-C only in the premenopausal women.
We determined a profound impact of APOE genotypes on WHR obesity index only in the early postmenopausal women. Mean WHR values were statistically significant between E2 and E4 groups, with the highest values recorded in the E2 carriers. In this respect, our results agree with Reilly et al. [25] . Their study was based on women in the 26 to 63 year age group, and they reported that the E*3/2 genotype was associated with a significantly higher average WHR value compared to E*3/3 and E*3/4 genotypes. The study "Atherosclerosis Risk in Communities" (ARIC) revealed that apoE isoforms are associated with increased BMI in the following order: APOE*2>APOE*3>APOE*4 [26] . That finding was not consistent with our results, where an effect of menopausal group and APOE group on BMI was not detected. Surekha et al. [27] established no significant relationship of APOE genotype with BMI in pre-and postmenopausal Indian women.
Our findings on the effects of APOE genotypes on WHR only in the early postmenopausal women suggest that there may be interrelationships between the APOE genotype, fat mass and sudden menopausal hormonal changes. However, since sex-steroid hormonal levels were not examined in our subjects, we were unable to confirm these associations. At this point in time, we are only able to support Mayes and Watson´s [28] explanation that although normal body fat distribution exists in the presence of sex steroid hormones, there is a tendency to increased central obesity with the decrease in sex steroid hormones that occurs in ageing and/or menopause. In our study, this effect was observed in the APOE*2 carriers. Quite surprisingly, the mean value of the central obesity indicator (WHR) was lower in the APOE*4 carriers. Based on results of a cross-sectional study of 113 Caucasian postmenopausal women aged 62.4±9.8 years published by Zofkova et al. [29] , women possessing the APOE*4 allele had significantly higher serum testosterone and dehydroepiandrosterone (DHEA) levels than those lacking the APOE*4 allele. Studies have reported that dehydroepiandrosterone-S (DHEA-S, DHEA metabolite) levels are higher in lean women than in obese ones [30, 31] . Denti et al. [30] documented a slightly negative correlation between DHEA-S and WHR, and Al-Harithy [31] reported a negative correlation between DHEA-S and BMI. DHEA administration in postmenopausal women has also been reported to decrease fat mass [32, 33] . We presume that E2 carriers are more likely to have lower levels of DHEA and/or other sex steroid hormones after menopause than E4 carriers, and they probably compensate for this deficit by accumulation of more adipose tissue, which is manifested in an increased WHR. But since we were unable to examine the hormonal profiles of subjects, further studies are needed to support this assumption.
Conclusions
The results of this study suggest that the APOE*2 allele has a protective effect against higher blood lipid and lipoprotein levels. Moreover, we document that the APOE*2 allele could have a partial negative effect on the WHR obesity index in early postmenopausal Slovak women (1-10 years after final menstrual period).
Since this study was limited by its cross-sectional design, further prospective association and followup investigations are desirable, especially to explore interrelationships between APOE polymorphism, sexsteroid hormones and fat mass accumulation.
